(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
2 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 14.63%
@ $16.91
发出时间: 14 Feb 2024 @ 04:46
回报率: -26.96%
上一信号: Feb 13 - 01:23
上一信号:
回报率: -5.11 %
Live Chart Being Loaded With Signals
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases...
Stats | |
---|---|
今日成交量 | 680 666 |
平均成交量 | 1.03M |
市值 | 437.20M |
EPS | $0 ( 2024-04-02 ) |
下一个收益日期 | ( $0 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.29 |
ATR14 | $0.0250 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-17 | Butler Thomas Andrew | Buy | 407 502 | Stock Option (Right to Buy) |
2024-01-17 | Erdtmann Rainer M | Buy | 135 700 | Stock Option (Right to Buy) |
2024-01-17 | Valle Franco | Buy | 145 245 | Stock Option (Right to Buy) |
2024-01-17 | Frias Juan Pablo | Buy | 111 090 | Stock Option (Right to Buy) |
2023-12-29 | Erdtmann Rainer M | Sell | 3 000 | Common Stock |
INSIDER POWER |
---|
34.13 |
Last 86 transactions |
Buy: 9 688 408 | Sell: 6 373 693 |
音量 相关性
Biomea Fusion, Inc. 相关性 - 货币/商品
Biomea Fusion, Inc. 财务报表
Annual | 2022 |
营收: | $0 |
毛利润: | $-1.26M (0.00 %) |
EPS: | $-2.73 |
FY | 2022 |
营收: | $0 |
毛利润: | $-1.26M (0.00 %) |
EPS: | $-2.73 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-3.88 |
FY | 2020 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.500 |
Financial Reports:
No articles found.
Biomea Fusion, Inc.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。